Related Experiment Video
Updated: Oct 12, 2025

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
Published on: January 31, 2018
Predictive and Experimental Immunogenicity of Burkholderia Collagen-like Protein 8-Derived Antigens
Megan E Grund1, Eliza Kramarska2, Soo Jeon Choi1
1Department of Microbiology, Immunology and Cell Biology, School of Medicine, West Virginia University, Morgantown, WV 26506, USA.
Abstract:
Burkholderia pseudomallei is an infectious bacterium of clinical and biodefense concern, and is the causative agent of melioidosis. The mortality rate can reach up to 50% and affects 165,000 people per year; however, there is currently no vaccine available. In this study, we examine the antigen-specific immune response to a vaccine formulated with antigens derived from an outer membrane protein in B. pseudomallei, Bucl8. Here, we employed a number of bioinformatic tools to predict Bucl8-derived epitopes that are non-allergenic and non-toxic, but would elicit an immune response. From these data, we formulated a vaccine based on two extracellular components of Bucl8, the β-barrel loops and extended collagen and non-collagen domains. Outbred CD-1 mice were immunized with vaccine formulations-composed of recombinant proteins or conjugated synthetic peptides with adjuvant-to assess the antigen-specific immune responses in mouse sera and lymphoid organs. We found that mice vaccinated with either Bucl8-derived components generated a robust TH2-skewed antibody response when antigen was combined with the adjuvant AddaVax, while the TH1 response was limited. Mice immunized with synthetic loop peptides had a stronger, more consistent antibody response than recombinant protein antigens, based on higher IgG titers and recognition of bacteria. We then compared peptide-based vaccines in an established C57BL/6 inbred mouse model and observed a similar TH2-skewed response. The resulting formulations will be applied in future studies examining the protection of Bucl8-derived vaccines.
Insights
A new vaccine targeting Burkholderia pseudomallei, the cause of melioidosis, shows promise. Synthetic peptide formulations elicited a strong antibody response in mice, paving the way for future protection studies.
Area of Science:
- * Infectious disease research
- * Vaccine development
- * Immunology
Background:
- * Burkholderia pseudomallei causes melioidosis, a severe infection with high mortality and no current vaccine.
- * Melioidosis affects 165,000 people annually, posing a significant clinical and biodefense challenge.
Purpose of the Study:
- * To investigate the antigen-specific immune response to a novel vaccine candidate for B. pseudomallei.
- * To evaluate vaccine formulations based on outer membrane protein Bucl8 components.
Main Methods:
- * Bioinformatic tools were used to predict non-allergenic, non-toxic epitopes from Bucl8.
- * Vaccines were formulated using extracellular Bucl8 components (β-barrel loops, collagen domains) as recombinant proteins or synthetic peptides with adjuvant.
- * Antigen-specific immune responses were assessed in mouse sera and lymphoid organs (CD-1 and C57BL/6 models).
Main Results:
- * Vaccination with Bucl8 components and AddaVax adjuvant induced a robust TH2-skewed antibody response, with limited TH1 response.
- * Synthetic loop peptides resulted in a stronger, more consistent antibody response (higher IgG titers) compared to recombinant proteins.
- * A similar TH2-skewed response was observed in the C57BL/6 mouse model using peptide-based vaccines.
Conclusions:
- * Bucl8-derived synthetic peptide vaccines elicit a significant antigen-specific antibody response in mouse models.
- * These findings support the further development of Bucl8-based vaccines for melioidosis protection.
More Related Videos
06:38Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
Published on: December 8, 2023
06:57Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
Related Concept Videos
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Cross-reactivity
Vaccinations